ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeReliable prognostic tools in ovarian cancer are urgently needed to guide risk-adapted treatment decisions, yet the clinical utility of urinary metabolites for noninvasive risk stratification remains largely undefined. Here, we define a clinically relevant urinary metabolite signature that enables noninvasive prognostic risk stratification in ovarian cancer. EXPERIMENTAL
designWe used targeted 1H nuclear magnetic resonance spectroscopy to profile 149 metabolites related to energy metabolism, oxidative stress, mitochondrial function, nitrogen metabolism, amino acid degradation, gut microbiome activity, and inflammation. Metabolites were measured in preoperative urine samples from 199 consecutive patients with newly diagnosed ovarian cancer treated in routine clinical practice between 2013 and 2022.
resultsUnsupervised clustering revealed biologically heterogeneous subgroups but lacked prognostic resolution and alignment with overt clinical phenotypes. However, single-metabolite analysis identified a condensed three-metabolite prognostic signature comprising glycine, alanine, and citrate. A final parsimonious model integrating this metabolite signature with clinical covariates outperformed established risk factors alone (Fédération Internationale de Gynécologie et d'Obstétrique stage and surgical outcome), accurately predicted 60-month overall survival (AUC = 0.839), and stratified risk. Patients in the highest-risk quartile (Q4) had markedly shorter progression-free survival [Δmedian ≈ 56 months; HR, 2.63; 95% confidence interval (CI), 1.54-4.52; P < 0.001] and overall survival (Δmedian ≈ 86 months; HR, 2.49; 95% CI, 1.39-4.46; P = 0.009) compared with the lowest-risk group (Q1).
conclusionsWe define a urinary three-metabolite signature that enables noninvasive identification of patients with high-risk ovarian cancer beyond established clinical factors. This signature may support molecular stratification and risk-adapted clinical decisions, thereby underscoring the clinical scalability of urine as a matrix for metabolic risk profiling in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.